Table 1.
Characteristics, methodological quality, treatment employed and outcome of the trials
| Trial | Reference | Recruitment period | Publication year | Trial size | Origin of study | Randomization method | Stratification criteria | Trial type | Stage | Fraction with squamous cell (%) | Details of neoadjuvant treatment | HRa(95% CI) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dautzenberg et al. |
10 |
1985 to 1987 |
1990 |
26 |
European |
No details given |
Not reported |
Full text |
Stage 1 to 3 |
81 |
VCP × 2 |
1.10 (0.41 to 2.93) |
| Roth et al. |
13,14 |
1987 to 1993 |
1998 |
60 |
US |
No details given |
Not reported |
Full text |
Stage 3 only |
37 |
CEP × 3 |
0.56 (0.31 to 1.01) |
| Rosell et al. |
11, 12 |
1989 to 1991 |
1999 |
60 |
European |
Details given |
Not reported |
Full text |
Stage 3 only |
70 |
MIP × 3 |
0.50 (0.30 to 0.85) |
| Zhou et al. |
21 |
1990 to 2001 |
2001 |
624 |
Asian |
Details given |
Not reported |
Full text |
Stage 3 only |
51 |
BAI/MVP/CAP/EP/VIP/GP/NP/PC/TN × 2 |
0.87 (0.71 to 1.07) |
| De Pierre et al. |
15 |
1991 to 1997 |
2002 |
355 |
European |
No details given |
Reported |
Full text |
Stage 1 to 3 |
74 |
MIP × 2 |
0.83 (0.64 to 1.07) |
| JCOG |
16 |
1993 to 1998 |
2003 |
62 |
Asian |
No details given |
Reported |
Full text |
Stage 3 only |
24 |
VP × 3 |
1.19 (0.69 to 2.05) |
| Li et al. |
24 |
1990 to 1995 |
2003 |
137 |
Asian |
No details given |
Not reported |
Full text |
Stage 3 only |
80 |
CAP/EP × 1 |
0.68 (0.46 to 1.00) |
| Liao et al. |
22 |
1995 to 1997 |
2003 |
211 |
Asian |
Details given |
Reported |
Full text |
Stage 1 to 3 |
- |
MVP/MAP × 2 |
1.06 (0.76 to 1.48) |
| Yao et al. |
23 |
1990 to 2002 |
2004 |
456 |
Asian |
Details given |
Not reported |
Full text |
Stage 3 only |
55 |
GP/NP/MVP/EP × 2 |
0.83 (0.67 to 1.03) |
| Sorensen et al. |
17 |
1998 to 2004 |
2005 |
90 |
US |
No details given |
Not reported |
Abstract |
Stage 1 to 3 |
- |
TP × 3 |
0.91 (0.55 to 1.50) |
| s9900 |
18,19 |
1999 to 2004 |
2006 |
336 |
European |
No details given |
Not reported |
Full text |
Stage 1 to 3 |
38 |
PC × 3 |
0.79 (0.60 to 1.06) |
| MRCLU22 |
6 |
1997 to 2005 |
2007 |
519 |
European |
No details given |
Not reported |
Full text |
Stage 1 to 3 |
49 |
MVP/MIP/NP/PC/DC/GP × 3 |
1.02 (0.80 to 1.31) |
| Ch.E.S.T |
20, 25 |
2000 to 2004 |
2008 |
270 |
European |
No details given |
Not reported |
Abstract |
Stage 1 to 3 |
41 |
GP × 3 |
0.63 (0.46 to 0.87) |
| Felip et al. | 26 | 2000 to 2007 | 2010 | 409b | European | No details given | Not reported | Full text | Stage 1 to 3 | 52 | PC × 3 | 0.96 (0.84 to 1.10) |
aHazard ratio for mortality.
bNumber of cases in surgery only, and neoadjuvant chemotherapy arms; excludes patients in the adjuvant chemotherapy arm.
BAI = bronchial artery infusion; CAP = cyclophosphamide, adriamycin, cisplatin; CEP = etoposide, cyclophosphamide, cisplatin; DC = docetaxel, carboplatin; EP = etoposide, cisplatin; GP = gemcitabine, cisplatin; MAP = mitomycin, adriamycin, cisplatin; MIP = mitomycin, ifosfamide, cisplatin; MVP = mitomycin, vindesine, cisplatin; NP = navelbine, cisplatin; PC = paclitaxel, carboplatin; TN = paclitaxel, navelbine; VCP = vindesine, cyclophosphamide, cisplatin; VIP = vindesine, ifosfamide, cisplatin; VP = vindesine, cisplatin.